🔎 Trials Near Me

Home › Chronic Subdural Hematoma › NCT07291427

Chronic Subdural Hematoma Embolization With Detachable Coils

RecruitingObservational study

Safety and Efficacy of Chronic Subdural Hematoma Embolization With Detachable Coils

Who can join

Ages 18 and older · All sexes

Full eligibility criteria
Inclusion criteria:

* Age ≥ 18
* Patients experiencing unilateral or bilateral non-acute subdural hematoma confirmed by CT imaging. Acute on Chronic or mixed density hematoma allowed.
* A clinical decision has been made to use coiling and/or embolics as treatment, with or without surgical debridement, independently as per standard of care and prior to enrollment in the study.
* Signed informed consent obtained by patient or Legal Authorized Representative (LAR)

Exclusion criteria:

* Primary acute SDH
* Prior MMAE in target territory
* Premorbid mRS \> 3
* Common carotid stenosis \>70% or prior carotid stent placement
* Significant medical contraindication to angiography (kidney failure/disease)
* Anatomical variations that would make MMA embolization difficult or unsafe
* Currently participating in an investigational (drug, device, etc.) clinical trial that may confound study endpoints
* Pregnancy
* Life expectancy ≤ 1 year

About the study

This is a prospective, multi-center, post market registry study designed to evaluate the safety and efficacy of treatment with Balt coils in patients with chronic subdural hematoma (cSDH).

What is being tested

Sponsor: Icahn School of Medicine at Mount Sinai · Participants: 150 · Started: Jun 2, 2026

Contact the study team

Official record on ClinicalTrials.gov — NCT07291427

Locations in the U.S.

ArizonaCarondelet Neurological Institute, Tucson (Not yet recruiting)
CaliforniaUniversity of California - San Deigo, San Deigo (Not yet recruiting)
John Muir Health, Walnut Creek
KentuckyUniversity of Louisville, Louisville (Not yet recruiting)
OklahomaOklahoma University Medical Center, Oklahoma City (Not yet recruiting)

Conditions

From ClinicalTrials.gov, data retrieved Oct 2, 2026. Each study sets its own eligibility; the study team decides who can join.